Project Grant R01HL174409
Award Date
7/22/24
Completion Date
4/30/25
Dollars Obligated
$2.6M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, DC, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $421,800 to Midwestern University to explore the effects of chronic intermittent hypoxia on cholinergic modulation at hypoglossal motoneurons. The project aims to determine changes in muscarinic acetylcholine receptor expression and cholinergic inputs to hypoglossal motoneurons in neonatal and adult mice exposed to chronic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $744,305.00 to the University of Virginia to conduct research on the molecular physiology and gene regulatory functions of PHOX2B-expressing retrotrapezoid nucleus (RTN) chemoreceptor neurons. The key objectives are to: 1) Determine how persistent expression of wild-type and disease-relevant mutant forms of PHOX2B regulates genes critical...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $644,687 to the University of Missouri System to investigate a critical forebrain-brainstem neural circuit that contributes to the adaptive and maladaptive cardiorespiratory responses to chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnea. The research aims to resolve how this "orexin-CRH-NTS" circuit facilitates the peripheral...
This National Heart, Lung, and Blood Institute (NHLBI) funded Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) seeks to develop a novel 3D dynamic MRI (3D-DMRI) scheme to quantify airway collapse in patients with obstructive sleep apnea (OSA). The $426,717 award from August 2024 to May 2029 will be used by The University of Iowa to systematically validate the 3D-DMRI approach and assess its clinical utility for characterizing patterns of airway collapse, both in the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $162,728 to the University of California, San Diego (UCSD) to conduct research on the cardiovascular impacts of comorbid obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD), known as overlap syndrome (OVS). The central hypothesis is that poor outcomes in OVS are driven by more pronounced right and left heart...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to determine the prevalence of undiagnosed obstructive sleep apnea (OSA) and its subtypes in primary care clinics, as well as develop efficient tools to identify OSA risk and subtypes. The total award amount is $740,271 with a project period from August 2024 to June 2029. The prime recipient, The Ohio State University,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $142,572 to Oklahoma State University to conduct research on the role of glial cell dysfunction in obesity-induced hypertension. The 5-year project aims to investigate the mechanisms by which microglial senescence and impaired astrocytic glutamate reuptake in the RVLM region of the brainstem contribute to increased sympathetic nerve activity and high blood...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $564,445 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Texas Health Science Center at Houston (UTHealth) to support a 7-year "Hypoxia-Inflammation Program" focused on targeting hypoxia-inducible factors (HIFs) for heart and lung disease. The program incorporates three complementary research projects: 1) Exploring the regulation of HIFs by prolyl hydroxylase domain enzymes (PHDs) during...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,415,112 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Board of Regents of the University of Nebraska, University of Nebraska Medical Center (UNMC) Division. The grant, awarded on September 17, 2024, aims to evaluate a telehealth-delivered adaptive intervention to promote continuous positive airway pressure (CPAP) therapy adherence and improve health outcomes for adults newly diagnosed...
This federal Project Grant award of $332,862.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, will support research to assess night-to-night variability in novel sleep disordered breathing severity metrics and their impact on daytime functioning. The study aims to characterize reliable biomarkers of obstructive sleep apnea (OSA) severity, as the current standard measure (Apnea-Hypopnea Index) underestimates...